PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management Finds Frost & Sullivan - Health plans require clear evidence of the clinical utility of biomarker tests -
Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management Finds Frost & Sullivan


NewswireToday - /newswire/ - Mountain View, CA, United States, 2012/09/25 - Health plans require clear evidence of the clinical utility of biomarker tests -

Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


With technological advances in diagnostics, physicians may shortly have real-time information about the tumor at various stages of patient management. Future cancer biomarker tests will also be multiplexed and comprise multiple biomarker types. As personalized medicine involves matching effective treatments to individuals based on their genetic disposition and other reliable factors, highly specific biomarkers are critical for identifying likely responders from non-responders.

New analysis from Frost & Sullivan's ( Analysis of the U.S. Cancer Biomarker Testing Market research finds that the health plan reimbursement market earned revenues of $7.86 billion in 2011 and estimates this to reach $11.46 billion in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.], with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Effective cancer patient management relies on specific and useful biomarkers that enable oncologists to diagnose, determine suitable therapies, continuously monitor response to therapy, or monitor tumor progression," said Frost & Sullivan Industry Analyst Winny Tan, Ph.D. "Consequently, personalized medicine is becoming a mainstream concept and the approaches to personalized medicine are increasingly understood by physicians and patients."

Market participants are gearing up for exciting times in the market, as generation sequencing becomes more affordable and cost competitive with the prices of current tests that look at a single-mutation. Additionally, the accelerated trend of out-licensing and therapy-companion diagnostic co-development across the industry is likely to raise the number of new cancer biomarker tests entering the market.

These new tests will be highly complex to perform and interpret. Following this, cancer testing will become centralized and more cancer biomarker tests are likely to be commercialized from multi-center research consortiums.

Furthermore, the large number and variety of industry partnerships suggest that collaboration is vital to compete in the market. Companies could partner with each other for companion diagnostic development, licensing agreements, clinical trial collaboration, R&D collaborations, distribution agreements, and other commercialization interests.

While technology is advancing cancer patient management, it is also escalating the costs of cancer biomarker testing. Currently, new detection platforms such as next-generation sequencing are still more expensive than traditional slide-based cancer testing, and this deters several potential buyer groups.

The commercial success of any diagnostic test depends on the clear evidence of its clinical utility; however, few biomarker discovery programs participate in the clinical validation of new biomarkers. The high costs of clinical validation and limited ROI are some of the reasons that few biomarkers have translated to diagnostic tests.

The market will also be affected by changes in the regulatory sphere. The increasing frequency of warning letters issued to clinical laboratories offering laboratory developed tests (LDTs) precedes the fact that the Food and Drug Administration (FDA) will exercise greater oversight over LDTs in the future. The final guidance on this issue will be announced by the FDA next year.

"Test developers should anticipate greater demands for proof for both assay performance and clinical utility," noted Tan. "Private and government health plans will require clear evidence of the clinical utility and the impact of the test on patient health to compare it with the best alternative."

Once participants demonstrate the value of new biomarker types, their pipeline will expand and subsequently, the market will grow at a faster rate.

Analysis of the U.S. Cancer Biomarker Testing Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: Analysis of the U.S. Clinical Laboratory Market, Diagnostics Testing and Technologies for Solid Tumor (FFPE) Specimens End-user Analysis, and Demand Analysis of U.S. Cancer Sample Prep Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

Analysis of the U.S. Cancer Biomarker Testing Market / NB1D-52

Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!

Advances in Biomarker Testing Drives Cancer Management to Soon Resemble Chronic Disease Management Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Britni Myers 
210-477-8481 britni.myers[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Health/Surgery Most Recent Related Newswires:

Lutein & Zeaxanthin Supplementation Could Save EU Billions in Healthcare Costs Associated with Age-related Macular Degeneration Says Frost & Sullivan
Frost & Sullivan Commends Columbia Pacific’s Clear Vision in the Healthcare Delivery Space and Senior Living Services
Global Acute Myeloid Leukemia Treatment Market to Reach US$ 1.17 Billion by 2021 According to iHealthcareAnalyst, Inc.
Frost & Sullivan Recognizes Prognos for its Commitment to Develop Novel Artificial Intelligence Based Platfor
DSM Partners with the Musculoskeletal Transplant Foundation for Distribution of Regenerative Materials and Products
Sturge-Weber Foundation and Lurie Children’s Hospital Host Sturge-Weber Syndrome Education Forum
USACS Announces New Integrated Acute Care Partnership with Sharon Regional Health System
Frost & Sullivan Highlights STANLEY Healthcare's Design Innovation and Leadership in Addressing the Changing Needs of the Senior Living Industry
USACS Additional Integrated Acute Care Partnership with MetroSouth Medical Center
Big Data Analytics to Disrupt U.S. Next-generation Sequencing Informatics Market with Double-digit Growth
Bionic Prosthetics Manufacturers Drive R&D Initiatives across Emerging Markets to Impel its Adoption
Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment
Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry
Therapist Launches Podcast to Reach Larger Audience
Top Innovative Health and Wellness Technologies to Accelerate Global Adoption of Precision Medicine Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  SKS Media | SKS Associates Ltd

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (